Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
IPO Year: 2020
Exchange: NASDAQ
Website: ayalapharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2021 | $22.00 | Buy | Maxim Group |
| 12/20/2021 | $18.00 | Buy | HC Wainwright & Co. |
| 11/30/2021 | $12.00 → $17.00 | Hold → Buy | Jefferies |
| 8/17/2021 | $27.00 → $25.00 | Outperform | Oppenheimer |
| 7/13/2021 | $29.00 | Buy | Ladenburg Thalmann |
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggress
3 - Old Ayala, Inc (0001797336) (Issuer)
3 - Old Ayala, Inc (0001797336) (Issuer)
3 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
SC 13G/A - Old Ayala, Inc (0001797336) (Subject)
SC 13G - Old Ayala, Inc (0001797336) (Subject)
SC 13G/A - Old Ayala, Inc (0001797336) (Subject)
SC 13G/A - Old Ayala, Inc (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX:ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the na
REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place in-person November 16-19 in Vancouver, Canada. The ongoing RINGSIDE Pivotal Phase 2/3 clinical trial is evaluating the investigational new drug AL102, a poten
REHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI). "We are pleased to begin enrollment in the Phase 3 segment of RINGSIDE, which is a significant milestone in our AL102 development program," said Roni Mamluk, Ph.D., President and Chief Exec
Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala's shareholders and the satisfaction of customary closing conditions Interim positive data from Part A of the RINGSIDE study presented at ESMO demonstrated substantial anti-tumor activity for AL102 as monotherapy and supports continued development AL102 granted Fast Track designation by U.S. FDA for the treatment of progressing desmoid tumors REHOVOT, Israel and WILMINGTON, Del., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule ther
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggress
Event will feature a review of data from part A of the Phase 2/3 RINGSIDE trial of AL102KOLs and management to present on Thursday, October 6th @ 8 AM ET REHOVOT, Israel and WILMINGTON, Del., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that it will host a key opinion leader (KOL) webinar on unmet medical needs and evolving treatment landscape of desmoid tumors on Thursday, October 6, 2022, at 8:00 am ET. The webinar will include presentations by Professors Bernd Kasper,
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AL102 for the treatment of progressing desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor. "We are pleased to receive FDA Fast Track designation for AL102 in progressing desmoid tumors, which we believe reinforces the large unmet medical need for patients with this serious disease.
REHOVOT, Israel and WILMINGTON, Del., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that data on the efficacy and tolerability of investigational new drug AL102 from Part A of the Phase 2/3 RINGSIDE study will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress, to take place September 8-13, 2022 in Paris, France. The presentation details follow: Abstract Title:Initial Results of Phase 2/3 Trial of AL102 for Treatment of Desmoid Tumors
Interim data from Part A of the RINGSIDE study demonstrated substantial initial anti-tumor activity for AL102 as a single agent and supports continued development More advanced and comprehensive data set from RINGSIDE to be presented at ESMO REHOVOT, Israel and WILMINGTON, Del., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced second-quarter 2022 financial results and provided a corporate update. "We continue to make considerable pr
Maxim Group initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $22.00
HC Wainwright & Co. initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $18.00
Jefferies upgraded Ayala Pharmaceuticals from Hold to Buy and set a new price target of $17.00 from $12.00 previously
Oppenheimer reiterated coverage of Ayala Pharmaceuticals with a rating of Outperform and set a new price target of $25.00 from $27.00 previously
Ladenburg Thalmann initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $29.00
Noble Financial resumed coverage of Ayala Pharmaceuticals with a rating of Buy
10-K - Old Ayala, Inc (0001797336) (Filer)
15-12G - Old Ayala, Inc (0001797336) (Filer)
8-K - Old Ayala, Inc (0001797336) (Filer)
EFFECT - Old Ayala, Inc (0001797336) (Filer)
EFFECT - Old Ayala, Inc (0001797336) (Filer)
POS AM - Ayala Pharmaceuticals, Inc. (0001797336) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001797336) (Filer)
POS AM - Ayala Pharmaceuticals, Inc. (0001797336) (Filer)
25-NSE - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
8-K - Ayala Pharmaceuticals, Inc. (0001797336) (Filer)